These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20578792)

  • 1. Global stability of an HIV-1 model with distributed intracellular delays and a combination therapy.
    Liu S; Wang L
    Math Biosci Eng; 2010 Jul; 7(3):675-85. PubMed ID: 20578792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
    Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
    AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
    [No Abstract]   [Full Text] [Related]  

  • 3. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 4. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 5. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 7. Periodic multidrug therapy in a within-host virus model.
    Browne CJ; Pilyugin SS
    Bull Math Biol; 2012 Mar; 74(3):562-89. PubMed ID: 21822766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global asymptotic stability for HIV-1 dynamics with two distributed delays.
    Wang J; Huang G; Takeuchi Y
    Math Med Biol; 2012 Sep; 29(3):283-300. PubMed ID: 21734220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decay characteristics of HIV-1-infected compartments during combination therapy.
    Perelson AS; Essunger P; Cao Y; Vesanen M; Hurley A; Saksela K; Markowitz M; Ho DD
    Nature; 1997 May; 387(6629):188-91. PubMed ID: 9144290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2004 Sep; 66(5):1259-83. PubMed ID: 15294425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy.
    Stellbrink HJ; Eggers C; van Lunzen J; Albrecht H; Greten H
    AIDS; 1997 Nov; 11(13):1655-7. PubMed ID: 9365775
    [No Abstract]   [Full Text] [Related]  

  • 13. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
    Wilkins E
    J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
    [No Abstract]   [Full Text] [Related]  

  • 14. Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
    Batisse D; Karmochkine M; Si Mohamed A; Piketty C; Kazatchkine MD; Belec L
    AIDS; 1998 May; 12(7):824-5. PubMed ID: 9619820
    [No Abstract]   [Full Text] [Related]  

  • 15. Explicitly accounting for antiretroviral drug uptake in theoretical HIV models predicts long-term failure of protease-only therapy.
    Smith RJ
    J Theor Biol; 2008 Mar; 251(2):227-37. PubMed ID: 18191950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protease inhibitors and mortality among children and adolescents infected with HIV-1.
    Barbaro G
    N Engl J Med; 2002 Mar; 346(13):1026-7; author reply 1026-7. PubMed ID: 11919316
    [No Abstract]   [Full Text] [Related]  

  • 18. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
    Clark NM; Dieng Sarr A; Sankalé JL; Kanki PJ; Kazanjian P; Winfield R; Markovitz DM
    AIDS; 1998 Dec; 12(18):2506-7. PubMed ID: 9875594
    [No Abstract]   [Full Text] [Related]  

  • 20. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.